Home > Insider Trading > Filing (0000874015-25-000057)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874015	Ionis Pharmaceuticals Inc	IONS	Pharmaceutical Preparations (2834)	330336973

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1970151	Brian Birchler	2855 Gazelle Court Carlsbad CA 92010	Evp, Corp And Development Ops	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-01-15	14,283	$0.00	60,451	No	4	M	Direct
Common Stock	Disposition	2025-01-16	5,400	$32.70	55,051	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Performance Restricted Stock Units	Acquisiton	2025-01-15	22,000	$0.00	22,000	$0.00
Common Stock	Restricted Stock Unit	Acquisiton	2025-01-15	33,000	$0.00	33,000	$0.00
Common Stock	Restricted Stock Unit	Disposition	2025-01-15	14,283	$0.00	14,283	$0.00

Remaning Holdings	Exercise Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
53,338	2028-01-15	No	4	A	Direct
77,373	2026-01-15	No	4	A	Direct
63,090	2025-01-15	No	4	M	Direct

Footnotes

Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.
The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.
Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.